TY - JOUR
T1 - Inference on the Genetic Architecture of Breast Cancer Risk
AU - Yasui, Yutaka
AU - Letsou, William
AU - Wang, Fan
AU - Im, Cindy
AU - Sapkota, Yadav
AU - Wang, Zhaoming
AU - Salehabadi, Sedigheh Mirzaei
AU - Baedke, Jessica L.
AU - Moon, Won Jong
AU - Liu, Qi
AU - Robison, Leslie L.
AU - Martinez, Jose Miguel
N1 - Publisher Copyright:
© 2023 American Association for Cancer Research.
PY - 2023/11/1
Y1 - 2023/11/1
N2 - Background: What are the major determinants of women’s breast cancer risk? Rare mutations such as those in the BRCA1/2 genes, polygenic scores of common alleles identified by genome-wide association studies, or nongenetic factors? Methods: The population-based Nordic Twin Study of Cancer, with 3,933 breast cancer cases among 21,054 monozygotic (MZ) and 30,939 dizygotic (DZ) female twin pairs, provides three key clues to this question: (i) the average lifetime risk, approximately 8%, does not differ by twin zygosity; (ii) the mean time interval between diagnoses when both twins develop disease (i.e., disease concordance) also does not differ by zygosity; but, (iii) conditioning on one twin having developed disease, the incidence rate in the co-twin is approximately 1% per year if the pair is MZ and 0.5% per year if DZ. Results: Assuming that nongenetic risk factors are shared similarly between twins regardless of zygosity, we can draw two conclusions from (i) to (iii). Conclusions: First, (i) and (iii) imply that the chief determinant of risk is in the germline DNA, because the conditional incidence rate is several-fold higher than the average risk (8% lifetime) in MZ twins but only half as much in DZ twins. Second, the seeming inconsistency between the two-fold conditional incidence rate (iii) and the equality of the mean inter-twin disease intervals in disease concordance (ii) can be resolved if the risk factors in the germline DNA are rare variants, not common variants. Impact: This paper details simple deductive reasoning for these conclusions and draws a critical inference regarding breast cancer etiology.
AB - Background: What are the major determinants of women’s breast cancer risk? Rare mutations such as those in the BRCA1/2 genes, polygenic scores of common alleles identified by genome-wide association studies, or nongenetic factors? Methods: The population-based Nordic Twin Study of Cancer, with 3,933 breast cancer cases among 21,054 monozygotic (MZ) and 30,939 dizygotic (DZ) female twin pairs, provides three key clues to this question: (i) the average lifetime risk, approximately 8%, does not differ by twin zygosity; (ii) the mean time interval between diagnoses when both twins develop disease (i.e., disease concordance) also does not differ by zygosity; but, (iii) conditioning on one twin having developed disease, the incidence rate in the co-twin is approximately 1% per year if the pair is MZ and 0.5% per year if DZ. Results: Assuming that nongenetic risk factors are shared similarly between twins regardless of zygosity, we can draw two conclusions from (i) to (iii). Conclusions: First, (i) and (iii) imply that the chief determinant of risk is in the germline DNA, because the conditional incidence rate is several-fold higher than the average risk (8% lifetime) in MZ twins but only half as much in DZ twins. Second, the seeming inconsistency between the two-fold conditional incidence rate (iii) and the equality of the mean inter-twin disease intervals in disease concordance (ii) can be resolved if the risk factors in the germline DNA are rare variants, not common variants. Impact: This paper details simple deductive reasoning for these conclusions and draws a critical inference regarding breast cancer etiology.
UR - https://www.scopus.com/pages/publications/85168825698
UR - https://www.scopus.com/pages/publications/85168825698#tab=citedBy
U2 - 10.1158/1055-9965.EPI-22-1073
DO - 10.1158/1055-9965.EPI-22-1073
M3 - Article
C2 - 36652676
AN - SCOPUS:85168825698
SN - 1055-9965
VL - 32
SP - 1518
EP - 1523
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
IS - 11
ER -